Timeline: Insulin Market Under Scrutiny

By Sarah Jane Tribble October 30, 2017

We encourage organizations to republish our content material, freed from cost. We don’t require a lot.

For those that must know the authorized underpinnings of utilizing our content material, we make it obtainable underneath the Creative Commons CC BY license. Here’s what we ask:

You should credit score us as the unique writer, with a hyperlink to our website: Kaiser Health News. If attainable, please embody the unique creator(s) and “Kaiser Health News” within the byline. If you’d like to clarify extra about who we’re, please use: “a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.” You could use our emblem when linking to or posting supplies in your website: Download high-resolution .PNG file

Please protect the hyperlinks within the story.

It’s essential to notice, not all the pieces on is our authentic content material or obtainable for republishing. If a narrative is labeled “All Rights Reserved,” KHN can not grant permission to republish that merchandise.

Have questions? Let us know at”>

Sarah Jane Tribble, Kaiser Health News

The value of lifesaving diabetes medication has skyrocketed over the previous decade. And sufferers aren’t the one ones who’ve observed. Five states and a federal prosecutor are demanding data from insulin producers and the pharmaceutical business’s monetary middlemen.

Below, we element when authorized motion associated to insulin medication started, with hyperlinks to paperwork.

March 2016

The U.S. Attorney’s Office for the Southern District of New York launches the primary of a number of civil investigative calls for (CIDs), starting with Sanofi and Novo Nordisk.

The be aware, like these of Eli Lilly and Sanofi, establishes that the federal prosecutor is within the firm’s enterprise relationships with pharmacy profit managers and calls for data on particular insulins.

The federal prosecutor’s demand of Novo Nordisk specifies data is required concerning insulins Novolog, Novolin and Levemir, in line with the company’s annual report; Sanofi experiences the request for data can be in relation to pharmacy profit managers and concerning top-selling insulin drug Lantus in addition to Apidra since 2006, in line with the company’s annual 20-F filing. July 2016 Eli Lilly discloses that the U.S. Attorney’s Office for the Southern District of New York issued a CID additionally for data associated to pharmacy profit managers, in line with its July 2016 quarterly filing. August 2016 Express Scripts receives a CID from the U.S. Attorney’s Office for the Southern District of New York. It too notes the federal prosecutor is asking for details about relationships. No particular medication are named, in line with the corporate’s 2016 annual report. November 2016 Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) ask the Department of Justice and the Federal Trade Commission  to research whether or not insulin makers have colluded or engaged in anti-competitive behavior. January 2017 Minnesota’s lawyer normal launches what seems to be the primary state investigation, issuing civil investigative calls for to Sanofi and Novo Nordisk.

Minnesota’s State Attorney General’s workplace seems as the primary state to subject a civil investigative demand in federal filings.

Sanofi specifies data is required concerning insulin medication Lantus and Toujeo, in line with the company’s 20-F filing. Novo Nordisk experiences the state lawmaker desires data referring to “pricing and trade practices” since  January 2008 to current concerning insulins Levemir and Tresiba, in line with the company’s annual report. On Jan. 30, lawyer Steve Berman of Hagens Berman files initial complaint within the U.S. District Court of Massachusetts towards insulin makers Novo Nordisk, Sanofi and Eli Lilly. He alleges an “organized scheme to drive up prices at the expense of patients who need insulin drugs to live.” The case later transfers to New Jersey. February 2017 Berman’s lawsuit is transferred to New Jersey and mixed with a associated case filed by lawyer James Cecchi, representing sufferers towards the insulin makers. March 2017 Washington’s lawyer normal points a CID to Sanofi echoing Minnesota’s request and specifying the request is for insulin medication Lantus, Toujeo, Apidra and Soliqua from 2005 to current, in line with the company’s half-year financial report. Frank Barnett and different sufferers file go well with March eight within the U.S. District Court of New Jersey towards the insulin producers, notably adding the nation’s largest pharmacy benefit managers Express Scripts, CVS Health and UnitedHealth Group as defendants.

Attorneys allege that the connection between drug producers and pharmacy profit managers harms sufferers and permits for rising insulin costs.

Julia Boss, the Type 1 Diabetes Defense Foundation and different sufferers file suit on March 17 within the U.S. District Court of New Jersey towards the three large insulin producers in addition to the pharmacy profit managers. April 2017 CVS Health receives a CID from Washington’s AG looking for data concerning pricing and rebates for insulin and epinephrine merchandise linked to a pending investigation. Under the bullet merchandise “Insulin Products Investigation,” CVS states that the Washington lawyer normal’s workplace will share data with the attorneys normal of California, Florida and Minnesota, which filed a CID in July. Scott Christensen and different sufferers file suit April 20 within the U.S. District Court of New Jersey alleging violations of the Sherman Antitrust Act. Defendants embody Novo Nordisk, Eli Lilly, Sanofi, Express Scripts, CVS Health, UnitedHealth Group with its PBM division OptumRx. May 2017 Eli Lilly doesn’t specify medication however confirms it has a obtained a CID from Washington’s lawyer normal concerning the “pricing of our insulin products and our relationships with pharmacy benefit managers.” It additionally states New Mexico’s lawyer normal issued a CID associated to “the pricing of our insulin products,” in line with its quarterly financial filing. July 2017 CVS Health receives a CID from Minnesota’s AG looking for data concerning pricing and rebates for insulin and epinephrine merchandise linked to a pending investigation, in line with a quarterly filing. Eli Lilly says it has obtained a CID from Minnesota’s AG “relating to the pricing and sale of our insulin products.” California and Florida’s attorneys normal requested data associated to pricing of insulin merchandise,  in line with its quarterly filing. Sen. Amy Klobuchar (D-Minn.) sends letters to insulin producers asking for “an explanation of the extreme price increases” of insulin.  Eli Lilly, Sanofi and Novo Nordisk every reply. September 2017 On Sept. 18, U.S. District Judge Brian Martinotti appoints Steve Berman and James Cecchi as interim lead counsel over a go well with that mixes the assorted civil lawsuits filed for the reason that starting of 2017 into one behemoth potential class-action go well with. Martinotti notes that the group of Berman and Cecchi “has successfully tried similar claims against comparable defendants.”

KHN’s protection of prescription drug improvement, prices and pricing is supported partially by the Laura and John Arnold Foundation.


Most Popular features the latest multimedia technologies, from live video streaming to audio packages to searchable archives of news features and background information. The site is updated continuously throughout the day.

Copyright © 2017 Breaking Express, Green Media Corporation

To Top